Skip to main content
D&D Pharmatech Inc. logo

D&D Pharmatech Inc. — Investor Relations & Filings

Ticker · 347850 ISIN · KR7347850000 KO Manufacturing
Open in API
Filings indexed 109 across all filing types
Latest filing 2021-03-31 Audit Report / Informat…
Country KR South Korea
Listing KO 347850

About D&D Pharmatech Inc.

http://www.ddpharmatech.com/

D&D Pharmatech is a clinical-stage biopharmaceutical company specializing in the development of therapies based on GLP-1 (Glucagon-like peptide-1) and related peptides. The company's pipeline primarily targets metabolic diseases, including obesity and MASH (Metabolic dysfunction-associated steatohepatitis), as well as neurodegenerative disorders. A core competency is its proprietary oral peptide delivery technology. Key candidates in its portfolio include DD01, an injectable dual GLP-1/glucagon receptor agonist for MASH that has received FDA Fast Track Designation, and an oral GLP-1 therapy for obesity. The company operates a global model, funding drug development through specialized subsidiaries, with research functions in Korea and clinical development managed by its US-based team.

Recent filings

Filing Released Lang Actions
감사보고서 (2020.12)
Audit Report / Information Classification · 1% confidence The document is a formal 'Audit Report' (감사보고서) for the company 'D&D Pharmatech' (주식회사 디앤디파마텍) for the fiscal year ending December 31, 2020. It includes the independent auditor's report, financial statements (balance sheet, income statement, statement of changes in equity, cash flow statement), and detailed notes. This is a comprehensive financial audit document, not an annual report (10-K) or a simple earnings release. FY 2020
2021-03-31 Korean
연결감사보고서 (2020.12)
Audit Report / Information Classification · 1% confidence The document is a comprehensive 'Audit Report' (감사보고서) for D&D Pharmatech, covering the fiscal years 2019 and 2020. It includes the independent auditor's report, consolidated financial statements (Statement of Financial Position, Statement of Comprehensive Income, Statement of Changes in Equity, Statement of Cash Flows), and detailed notes to the financial statements. While it contains financial data, it is specifically structured as an audit report package rather than a full Annual Report (10-K) or a quarterly interim report. According to the provided definitions, standalone audit reports and results of financial statements are classified as 'AR'. FY 2020
2021-03-31 Korean
감사보고서 (2019.12)
Audit Report / Information Classification · 1% confidence The document is a formal 'Audit Report' (감사보고서) for D&D Pharmatech for the fiscal year 2019. It includes the independent auditor's report, financial statements (Statement of Financial Position, Statement of Comprehensive Income, Statement of Changes in Equity, Statement of Cash Flows), and detailed notes to the financial statements. This is a comprehensive financial reporting document, not an announcement or a summary, and fits the definition of an Audit Report/Information (AR). FY 2019
2020-04-07 Korean
연결감사보고서 (2019.12)
Audit Report / Information Classification · 1% confidence The document is a comprehensive 'Consolidated Audit Report' (연결감사보고서) for D&D Pharmatech for the fiscal year 2019. It includes the independent auditor's report, consolidated financial statements (balance sheet, income statement, statement of changes in equity, cash flow statement), and detailed notes. While it contains financial data, it is a formal audit report rather than a quarterly report or a full 10-K annual report. Given the specific category definitions, 'AR' (Audit Report / Information) is the most accurate classification for a standalone audit report. FY 2019
2020-04-07 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.